In the twentieth century vaccine development has moved from the use of attenuated or killed
micro‐organisms to protein sub‐unit vaccines, with vaccine immunogenicity assessed by …

The vaccine discovery paradigm in tuberculosis (TB) has been to mimic the natural immune
response to infection. With an emphasis on interferon (IFN)-γ as the main protective …

Abstract The bacille Calmette–Guérin vaccine provides very efficient protection in standard
animal models of Mycobacterium tuberculosis challenge. We show in this article that …

Recent insights into the mechanisms by which Mycobacterium tuberculosis, the etiologic
agent of human tuberculosis, is recognized by cytosolic nucleotide sensors have opened …

Studies on mucosal-associated invariant T cells (MAITs) in nonhuman primates (NHP), a
physiologically relevant model of human immunity, are handicapped due to a lack of …

ABSTRACT Bacillus Calmette-Guérin (BCG) is the only licensed vaccine against
tuberculosis (TB). However, BCG has variable efficacy and cannot completely prevent TB …

Mycobacterium tuberculosis has evolved from a Mycobacterium canettii‐like progenitor pool
into one of the most successful and widespread human pathogens. The pathogenicity of M …

Performance of interferon-γ (IFN-γ) release assays still needs to be improved. The data on
the performance of QuantiFERON-TB Gold Plus (QFT-Plus), a new-generation of QFT assay …

The 6-kDa early secreted antigenic target (ESAT-6; EsxA) of Mycobacterium tuberculosis
was first identified as a potent T-cell antigen, and it is now recognized as a pore-forming …

There is an urgent need for the rational design of safe and effective vaccines to protect
against chronic bacterial pathogens such as Mycobacterium tuberculosis. Advax™ is a …